Who makes TAC,TC,TA,CAF,CEF?

TAC,TC,TA,CAF,CEF is developed by Shandong Cancer Hospital and Institute.

What development phase is TAC,TC,TA,CAF,CEF in?

TAC,TC,TA,CAF,CEF is in Phase 3.

What are the side effects of TAC,TC,TA,CAF,CEF?

Common side effects include Neutropenia, Anemia, Thrombocytopenia, Nausea and vomiting, Alopecia, Cardiotoxicity.

Last reviewed 2026-04-23 · How we verify

TAC,TC,TA,CAF,CEF

Shandong Cancer Hospital and Institute · Phase 3 active Small molecule

TAC/TC/TA/CAF/CEF are chemotherapy regimens combining docetaxel, doxorubicin, and cyclophosphamide with or without fluorouracil and epirubicin for cancer treatment.

TAC/TC/TA/CAF/CEF are chemotherapy regimens combining docetaxel, doxorubicin, and cyclophosphamide with or without fluorouracil and epirubicin for cancer treatment. Used for Breast cancer (likely primary indication based on TAC regimen use), Other solid tumors (specific indications unknown).

At a glance

Generic name	TAC,TC,TA,CAF,CEF
Also known as	1.TAC(docetaxel/doxorubicin/cyclophosphamide), 2.TC(docetaxel/cyclophosphamide), 3.TA(paclitaxel/doxorubicin), 4.CAF(fluorouracil/doxorubicin/cyclophosphamide), 5.CEF(cyclophosphamide/epirubicin//fluorouracil)
Sponsor	Shandong Cancer Hospital and Institute
Drug class	Chemotherapy regimen (multi-agent)
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

These are multi-drug chemotherapy combinations used in oncology. TAC (docetaxel, doxorubicin, cyclophosphamide) and its variants work through multiple mechanisms: cyclophosphamide is an alkylating agent, doxorubicin and epirubicin are anthracyclines that intercalate DNA, and docetaxel/fluorouracil are microtubule stabilizers and antimetabolites respectively. The combinations are designed to provide synergistic cytotoxic effects against rapidly dividing cancer cells.

Approved indications

Breast cancer (likely primary indication based on TAC regimen use)
Other solid tumors (specific indications unknown)

Common side effects

Neutropenia
Anemia
Thrombocytopenia
Nausea and vomiting
Alopecia
Cardiotoxicity
Mucositis

Key clinical trials

Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TAC,TC,TA,CAF,CEF CI brief — competitive landscape report
TAC,TC,TA,CAF,CEF updates RSS · CI watch RSS
Shandong Cancer Hospital and Institute portfolio CI